4-Repeat Tauopathy Neuroimaging Initiative - Cycle 2

Status:	Recruiting
Conditions:	Neurology, Neurology, Neurology, Neurology
Therapuetic Areas:	Neurology
Healthy:	No
Age Range:	40 - 80
Updated:	9/19/2018
Start Date:	January 2016
End Date:	December 2021
Contact:	Eliya Ben-Asher, BS
Email:	Eliya.Ben-Asher@ucsf.edu
Phone:	(415) 476-2941

The Four-Repeat Tauopathy Neuroimaging Initiative

The goal of this study is to identify the most reliable methods of analysis for tracking CBD,
PSP, and o/vPSP over time. The results from this study may be used in the future to calculate
statistical power for clinical drug trials. The study will also provide information about the
relative value of novel imaging techniques for diagnosis, as well as the value of imaging
techniques versus testing of blood, urine, and cerebrospinal fluid (CSF) 'biomarkers'.

Inclusion Criteria:

- No known history of neurological disease, or meet criteria for one of the following:
Corticobasal Syndrome or Degeneration (CBS or CBD); Progressive Supranuclear Palsy
(PSP); or Oligo- or Variant- Progressive Supranuclear Palsy (o/vPSP)

- Needs a reliable study partner who has frequent contact with the participant, who is
available to provide information about the participant, and who can accompany the
participant to research visits as needed

- Must be willing and able to undergo testing procedures, which include longitudinal
follow-up visits

- Must be able to walk five steps with minimal assistance

Exclusion Criteria:

- Significant neurological disease other than CBD, PSP, or a variant PSP syndrome.

- Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, or
metal fragments or metal objects in the eyes, skin, or body

- In the site investigator's opinion, inability to complete sufficient key study
procedures, or some other equivalent assessment of impairment

We found this trial at

sites

Mayo Clinic Rochester

200 First Street SW
Rochester, Minnesota 55905

507-284-2511